Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Views
administrator
administrator
07/14/23

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patientsโ€ฆ

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next